A new study has looked at how certain gene variants may predict whether an individual is likely to develop age-related macular degeneration (AMD). This eye disease affects over nine million Americans, but it has been found that certain ...
Researchers at the National Institutes of Health (NIH) have begun enrolling volunteers for clinical trials to find effective treatments for influenza. One of the studies will assess if treatment with the influenza drug oseltamivir reduces ...
Epic Sciences, a developer of diagnostic tests, has received a Phase II small business innovation research (SBIR) contract from the National Cancer Institute (NCI) and the National Institutes of Health (NIH) for the development of a lung ...
Tags: lung cancer diagnostic, blood test, Epic
The National Cancer Institute (NCI) and the National Institutes of Health (NIH) have announced a Phase II small business innovation research (SBIR) contract to Epic Sciences for the development of a lung cancer diagnostic blood test. The ...
Genea Stem Cells Pty Ltd (GSC), a supplier and developer of disease-specific human stem cells, has announced that 25 of its disease specific embryonic pluripotent stem cell lines have been placed on the USA National Institutes of Health ...
Thoratec has gained an investigational device exemption(IDE)from the US Food and Drug Administration(FDA)for the initiation of a feasibility clinical study of its continuous-flow left ventricular assist device(LVAD),for the treatment of ...
Edison Pharmaceuticals has started a phase 2B study, which will investigate new treatments for Friedreich's ataxia. The trial is entitled Safety and Efficacy Study of EPI-743 on Visual Function in Patients with Friedreich's Ataxia. It is ...
Tags: Edison Pharmaceuticals, disease severity, neuromuscular function
A new government study is warning that the Federal Communications Commission's standards for testing cell phones for exposure to radio-frequency energy may have fallen out of step with the latest scientific studies, calling on the agency to ...
Tags: Federal Communications Commission, cell phones, radio frequency energy
Thermedical has obtained 510(k) clearance for its radiofrequency-based thermal ablation system, designed for treating large volumes of solid tumors, from the US Food and Drug Administration (FDA). Featuring a single or more needles, the ...
Tags: Thermedical, thermal ablation system, FDA, radiofrequency waves, approval
Diagnos has initiated a new screening program for the prevention of diabetic retinopathy and vision loss in Canada. Under the new 'BEAT IT IN A BLINK' program, the company will make use of its proprietary Computer Assisted Retinal ...
Tags: Diagnos, screening program, diabetic retinopathy, vision loss
Stryker Neurovascular has obtained the US Food and Drug Administration's (FDA) approval for its new clot removal technology, Trevo Pro Retriever. By utilizing proprietary Stentriever technology, the Trevo Pro Retriever removes blood clots ...
Tags: Stryker Neurovascular, FDA, approval, clot removal technology
National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),US, has awarded $500,000 small business innovation research (SBIR) grant to Genalyte to develop multiplexed diagnostic assays for the ...
Tags: diabetes, digestive, kidney diseases, health
National Institutes of Health(NIH),under the SHIFT initiative,has granted two Small Business Innovative Research(SBIR)Phase I awards,totaling$800k over 2 years,to Circulomics. Circulomics will use the grants to develop its Ligo-miR ...
Tags: NIH, SHIFT, SBIR, Ligo miR microRNA assay technology
Fraunhofer Center for Molecular Biotechnology (FhCMB) has received a contract from the US National Institute of Allergy and Infectious Diseases to develop vaccine technologies for advancing the next generation of anthrax vaccines. ...
Tags: FhCMB, anthrax vaccines, NIH
The US Food and Drug Administration (FDA) has cleared Sigma-Tau Pharmaceuticals' topical ophthalmic therapeutic to treat corneal cystine crystals in cystinosis patients. The CYSTARAN 0.44% solution, which is developed in collaboration ...